Drug profile · INN
ceftolozane sulfate
ZERBAXA
ceftolozane sulfate (ZERBAXA) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Drug details — ceftolozane sulfate
- US status
- approved
- Class
- —
- Route
- INTRAVENOUS
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
ceftolozane sulfate (ZERBAXA) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
Key facts
Mechanism of action
Bacterial penicillin-binding protein inhibitor
Primary target: Bacterial penicillin-binding protein
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is ceftolozane sulfate?
ceftolozane sulfate (ZERBAXA) is a bacterial penicillin-binding protein inhibitor. Route of administration: intravenous. Current US regulatory status: approved.
What is the brand name for ceftolozane sulfate?
ZERBAXA is a marketed brand name for ceftolozane sulfate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of ceftolozane sulfate?
ceftolozane sulfate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.